article · Pharmaceuticals
Researchers evaluated a series of novel thiazole-based chalcone compounds for their potential as anticancer agents and tubulin polymerisation inhibitors. In laboratory screenings, derivatives designated 2a through 2p displayed broad-spectrum antitumour activity across multiple cancer cell lines, performing notably well against Ovar-3 ovarian cancer cells and MDA-MB-468 breast cancer cells. Among the tested molecules, compound 2e showed significant inhibition of tubulin polymerisation, achieving an IC50 of 7.78 micromolar compared to the reference compound Combretastatin-A4. Molecular docking simulations indicated that compounds 2e, 2g, and 2h bind effectively to the colchicine binding site on tubulin, mimicking the interactions seen with the reference drug. In addition, computational analyses suggested that these molecules possess favourable oral bioavailability and drug-likeness, supporting their continued exploration as candidates for chemotherapeutic development.
Disrupting tubulin polymerisation is an established strategy for stopping cancer cells from dividing and multiplying. Discovering new chemical compounds that target this mechanism, while also offering favourable oral bioavailability, helps expand the pipeline of potential chemotherapy candidates. This research provides initial molecular leads that could eventually inform the design of more effective or versatile cancer treatments.
This work represents very early-stage preclinical drug discovery. The findings identify candidate lead molecules that could interest pharmaceutical companies or oncology research teams developing tubulin-targeting therapies. However, real-world therapeutic application remains distant, as these compounds require extensive subsequent testing, including in vivo efficacy studies, toxicity evaluation, and formal clinical trials, before any commercial development as oral chemotherapeutics could proceed.
AI-generated from the published abstract. Always read the original work before citing.
A series of novel thiazole-based chalcones were evaluated for their anticancer activity as potential tubulin polymerization inhibitors. In vitro anticancer screening for the thiazole derivatives <b>2a</b>-<b>2p</b> exhibited broad-spectrum antitumor activity against various cancer cell lines particularly Ovar-3 and MDA-MB-468 cells with a GI<sub>50</sub> range from 1.55 to 2.95 μΜ, respectively. Compound <b>2e</b> demonstrated significant inhibition of tubulin polymerization, with an IC<sub>50</sub> value of 7.78 μM compared to Combretastatin-A4 (CA-4), with an IC<sub>50</sub> value of 4.93 μM. Molecular docking studies of compounds <b>2e</b>, <b>2g</b>, and <b>2h</b> into tubulin further supported these findings, revealing that they bind effectively to the colchicine binding site, mirroring key interactions exhibited by CA-4. Computational predictions suggested favorable oral bioavailability and drug-likeness for these compounds, highlighting their potential for further development as chemotherapeutic agents.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph17091154
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
